This report is a result of an on-site inspection conducted for the approval to use a narcotic agent, specifically buprenorphine, in the treatment of narcotic addiction. This inspection was conducted on April 1, 2008, by staff from the Division of Drug and Alcohol Program Licensure. Based on the findings of the on-site inspection which included a review of facility policies and procedures, Mirmont was found to be in compliance with the applicable chapters of 28 PA Code which pertain to the facility. Mirmont has not provided buprenorphine services since the initial approval on May 24, 2005. No deficiencies were identified during this inspection
|
Plan of Correction
|